Product
CLDN6
1 clinical trial
1 indication
Indication
Solid TumorClinical trial
Phase I/IIa, First-in-human (FIH), Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of CLDN6 CAR-T With or Without CLDN6 RNA-LPX in Patients With CLDN6-positive Relapsed or Refractory Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2027-01-01